Table 1.
Characteristics of the included studies.
| Study ID | Sample Size (E/C) | Sex (M/F) | Age (Year, E/C) | Intervention of experimental group | Intervention of control group | Course (Months) | Outcomes |
|---|---|---|---|---|---|---|---|
| Du JH 2018 (18) | 48/48 | (29/19)/(30/18) | (64.2 ± 4.3)/(62.7 ± 4.0) | CXC | CD | 1 | ① |
| Huang W 2021 (19) | 30/30 | (17/13)/(18/12) | (52.85 ± 6.38)/(51.86 ± 6.16) | CXC+CD | CD | 5 | ① ③ ④ ⑤ ⑥ ⑦ |
| An LN 2020 (20) | 35/35 | (19/16)/(20/15) | (51.17 ± 17.83)/(52.12 ± 15.76) | CXC+CD | CD | 3 | ① ④ ⑥ ⑦ |
| Wang J 2020 (21) | 44/42 | (26/19)/(23/19) | (69.52 ± 7.11)/(68.35 ± 6.82) | CXC+CD | CD | 5 | ① ③ ④ ⑤ ⑥ ⑦ |
| Yan H 2020 (22) | 46/46 | (27/19)/(25/21) | (48.5 ± 4.9)/(47.4 ± 4.6) | CXC+CD | CD | 3 | ① ⑦ |
| Chai F 2018 (23) | 54/53 | (32/22)/(30/23) | (61.11 ± 6.01)/(61.19 ± 6.03) | CXC+CD | CD | 3 | ① ③ ⑤ ⑥ |
| Wang Q 2018 (24) | 50/50 | (26/24)/(27/23) | (55.02 ± 2.58)/(54.80 ± 2.61) | CXC+CD | CD | 6 | ① ③ ④ ⑤ ⑥ |
| Ma JP 2018 (25) | 27/27 | (16/11)/(15/12) | (53.02 ± 4.13)/(53.08 ± 4.25) | CXC+CD | CD | 5 | ① ③ ④ ⑤ ⑥ ⑦ |
| Yu W 2017 (26) | 34/34 | (19/15)/(17/17) | (57.4 ± 8.3)/(58.1 ± 7.9) | CXC+CD | CD | 3 | ① ③ ⑤ ⑥ |
| Rao XJ 2017 (27) | 110/125 | (61/49)/(68/57) | (49.5 ± 5.9)/(50.2 ± 6.4) | CXC+CD | CD | 3 | ① |
| Men LB 2020 (28) | 40/40 | (21/19)/(22/18) | (66.97 ± 2.86)/(67.46 ± 2.52) | CXC+CD | CD | 2 | ① ② ③ ⑤ ⑥ |
| Li Y 2019 (29) | 49/49 | (28/21)/(27/22) | (66.82 ± 4.03)/(66.41 ± 4.11) | CXC+CD | CD | 3 | ① ③ |
| Pei R 2015 (30) | 32/32 | (17/15)/(16/16) | (56.4 ± 2.1)/(55.3 ± 1.2) | CXC+CD | CD | 5 | ① ③ ④ ⑤ ⑥ ⑦ |
| Zhou YD 2022 (31) | 63/63 | (34/29)/(35/28) | (51.14 ± 8.1)/(52.04 ± 2.2) | CXC+CD | CD | 3 | ① ③ ④ ⑤ ⑥ ⑦ |
| Luo D 2015 (32) | 28/29 | (18/10)/(19/10) | (59.54 ± 7.46)/(57.86 ± 10.03) | CDDP | CD | 3 | ③ |
| Jin M 2009 (33) | 30/28 | NR | (62.78 ± 7.69)/(61.11 ± 7.27) | CDDP | CD | 3 | ② ③ ⑤ |
| Chen Y 2006 (34) | 31/32 | (17/14)/(15/17) | (54.60 ± 10.40)/(58.12 ± 9.31) | CDDP | CD | 3 | ① |
| Xu HT 2019 (35) | 43/43 | (24/19)/(25/18) | (53.11 ± 4.41)/(53.06 ± 4.39) | CDDP+CD | CD | 4 | ① ③ ④ ⑤ ⑥ ⑦ |
| Li Y 2017 (36) | 89/89 | (31/58)/(28/61) | (56.5 ± 7.2)/(55.8 ± 6.8) | CDDP+CD | CD | 2 | ① |
| Wang HM 2016 (37) | 45/45 | (23/22)/(24/21) | (57.15 ± 6.68)/(57.06 ± 6.72) | CDDP+CD | CD | 2 | ① |
| Bai YX 2017 (38) | 38/38 | (20/18)/(21/17) | (40-72)/(39-71) | CDDP+CD | CD | 4 | ① ② ③ ④ ⑤ ⑦ |
| Ruan YX 2017 (39) | 35/35 | (18/17)/(20/15) | (52.5 ± 1.1)/(52.8 ± 1.7) | CDDP+CD | CD | 4 | ① ③ ④ ⑤ ⑥ ⑦ |
| Huang YX 2021 (40) | 45/45 | (28/17)/(29/16) | (67.5 ± 5.3)/(67.3 ± 5.1) | CDDP+CD | CD | 6 | ② ③ ④ ⑦ |
| Qin YH 2010 (41) | 414/221 | NR | NR | SDMUC | CD | 4 | ① ⑦ |
| Ji XD 2022 (42) | 52/52 | (29/23)/(28/24) | (56.63 ± 4.02)/(56.53 ± 4.09) | SDMUC+CD | CD | 3 | ① ⑤ ⑥ ⑦ |
| Liu JP 2019 (43) | 60/60 | (33/27)/(32/28) | (57.54 ± 8.11)/(57.10 ± 9.26) | SDMUC+CD | CD | 4 | ① ⑤ ⑥ ⑦ |
| Jin L 2019 (44) | 72/71 | (44/28)/(43/28) | (63.07 ± 8.08)/(62.39 ± 8.34) | SDMUC+CD | CD | 4 | ⑦ |
| Pang YH 2015 (45) | 40/40 | (18/22)/(16/24) | (49.4 ± 5.7)/(49.6 ± 5.3) | SDMUC+CD | CD | 4 | ① |
| Zhang DX 2015 (46) | 60/59 | (24/36)/(24/35) | (60.03 ± 6.11)/(60.79 ± 642) | QG | CD | 3 | ① |
| Fang J 2022 (47) | 51/51 | (27/24)/(26/25) | (45.5 ± 1.3)/(50.0 ± 1.4) | QG | CD | 6 | ① ⑦ |
| Duan JG 2006 (48) | 107/105 | NR | NR | QG | CD | 3 | ⑦ |
| Fan YP 2018 (49) | 47/47 | (26/21)/(27/20) | (48.6 ± 5.1)/(47.5 ± 4.9) | QG | CD | 6 | ① ⑥ ⑦ |
| Feng JL 2016 (50) | 42/41 | (29/13)/(27/14) | (55.26 ± 6.29)/(55.89 ± 6.13) | QG+CD | CD | 3 | ① ② |
| Wang ZQ 2019 (51) | 52/48 | (31/21)/(29/19) | (66.7 ± 6.2)/(66.8 ± 6.3) | QG+CD | CD | 6 | ① |
| Wang ZZ 2017 (52) | 47/47 | (29/18)/(26/21) | (54.5 ± 4.8)/(54.3 ± 4.9) | QG+CD | CD | 3 | ⑦ |
| Sui HL 2014 (53) | 43/43 | (22/21)/(23/20) | (50.22 ± 14.82)/(50.53 ± 11.28) | QG+CD | CD | 6 | ① ② |
| Yan JH 2020 (54) | 41/41 | (24/17)/(25/16) | (56.65 ± 4.02)/(56.96 ± 4.59) | QG+CD | CD | 2 | ① ② ⑦ |
| Ye XL 2019 (55) | 88/88 | (46/42)/(50/38) | (60.5 ± 13.4)/(60.9 ± 12.7) | HXMMT+CD | CD | 3 | ① |
| Gao L 2020 (56) | 128/128 | (75/53)/(72/56) | (58.14 ± 7.63)/(57.65 ± 7.82) | HXMMT+CD | CD | 3 | ① ③ ④ ⑤ ⑥ ⑦ |
| Zhu HM 2013 (57) | 30/30 | (13/17)/(14/16) | (61.5 ± 13.1)/(61.6 ± 12.7) | DHHYK | CD | 3 | ① ② |
| Li JB 2019 (58) | 54/54 | (29/25)/(28/26) | (55.4 ± 3.1)/(56.1 ± 3.7) | MMDHP+CD | CD | 5 | ① ③ ④ ⑤ ⑥ ⑦ |
| A YN 2019 (59) | 50/50 | (20/30)/(22/28) | (52.61 ± 5.39)/(53.02 ± 5.41) | MMDHP+CD | CD | 1 | ③ ④ ⑤ ⑥ |
E/C, experimental group/control group; M/F, male/female; OCPMs, oral Chinese patent medicines; NR, Not Reported; CD, calcium dobesilate; CXC, Compound Xueshuantong Capsule; CDDP, Compound Danshen Dripping Pill; SDMUC, Shuangdan Mingmu Capsule; QG, Qiming Granule; HXMMT, Hexuemingmu Tablet; DHHYK, Danhong Huayu Koufuye; MMDHP, Mingmu Dihuang Pill; ①Clinical effective rate; ②Visual acuity; ③visual field gray value; ④microaneurysm volume; ⑤hemorrhage area; ⑥macular thickness; ⑦adverse events rate